Assessing the financial impact of Translational Pharmaceutics®
Unlock the multi-million dollar benefits of Translational Pharmaceutics®, demonstrated in the Tufts CSDD study
Download the white paper today!
What can I learn?
Discover how to benefit from:
- A faster approach to drug development and accelerated time to market
- Average timeline savings of >12 months
- R&D spend reduced by $9.5 million for each month of time saved
- Total financial gains per drug approved >$100 million
- Formulations selected using clinical data, ensuring greater chances of success
- An integrated development model and simplified supply chain
About Translational Pharmaceutics®
Translational Pharmaceutics® accelerates drug development by integrating formulation development, real-time manufacturing, and clinical testing. Over the past decade, it has been used widely by pharmaceutical and biotech companies on >400 programs to advance molecules across the full development cycle, from first-in-human (FIH) trials to market. Key applications within the development process include:
- Transitioning molecules from FIH to proof of concept (POC)
- Development and optimization of clinical formulations
About the Tufts CSDD study
The Tufts CSDD compared the cycle times of traditional drug development programs to Translational Pharmaceutics® programs and their derivative effects on development economics. These data were incorporated in a drug development model and the financial benefits were quantified on industry R&D costs and returns. The model assessed several different project types and the top line results included mean financial benefits exceeding $100 million and mean timeline savings of >12 months.
Learn more about Translational Pharmaceutics
Latest news and events
-
NewsTufts CSDD Demonstrates Multi-Million Dollar Benefits of Translational Pharmaceutics®Tufts Center for the Study of Drug Development (CSDD) today published a white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms.
-
Nov 28Tradeshow & ConferenceBOS Manchester 2023 | Manchester, UKQuotient Sciences will be exhibiting at the upcoming BOS Manchester between 28th - 29th November in Manchester, UK. Connect with our drug development experts there.
-
Info SheetTranslational Pharmaceutics® Fact SheetQuotient Sciences helps you achieve your goals by enabling precise formulation development, streamlined manufacturing, quick pivot to clinical data and a significantly faster transition through drug development.
-
News3 Key Trends Shaping Our Industry: Contract Pharma Thought Leadership Feature with Eleanor RowQuotient Sciences’ Executive Director of Commercial, Eleanor Row, offers her thought leadership in Contract Pharma on the 3 key trends shaping our industry.